BR112022026086A2 - Métodos para tratar câncer ou doença de von-hippel lindau e para tratar carcinoma de célula renal, kit, e, uso de uma combinação terapêutica - Google Patents

Métodos para tratar câncer ou doença de von-hippel lindau e para tratar carcinoma de célula renal, kit, e, uso de uma combinação terapêutica

Info

Publication number
BR112022026086A2
BR112022026086A2 BR112022026086A BR112022026086A BR112022026086A2 BR 112022026086 A2 BR112022026086 A2 BR 112022026086A2 BR 112022026086 A BR112022026086 A BR 112022026086A BR 112022026086 A BR112022026086 A BR 112022026086A BR 112022026086 A2 BR112022026086 A2 BR 112022026086A2
Authority
BR
Brazil
Prior art keywords
von
methods
treat
kit
lindau disease
Prior art date
Application number
BR112022026086A
Other languages
English (en)
Inventor
Fleury PERINI Rodolfo
M Pinheiro Elaine
Willemann Rogerio Jaqueline
Original Assignee
Merck Sharp & Dohme Llc
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme Llc, Eisai R&D Man Co Ltd filed Critical Merck Sharp & Dohme Llc
Priority claimed from PCT/US2021/038171 external-priority patent/WO2021262562A2/en
Publication of BR112022026086A2 publication Critical patent/BR112022026086A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2857—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against nuclear receptors, e.g. retinoic acid receptor [RAR], RXR, orphan receptor

Abstract

MÉTODOS PARA TRATAR CÂNCER OU DOENÇA DE VON-HIPPEL LINDAU E PARA TRATAR CARCINOMA DE CÉLULA RENAL, KIT, E, USO DE UMA COMBINAÇÃO TERAPÊUTICA. São aqui providos métodos para tratar câncer (por exemplo, RCC) ou doença de von-Hippel Lindau, que compreendem administrar a um paciente humano em necessidade dos mesmos: (a) um antagonista de PD-1; (b) um inibidor de HIF-2a; e (c) lenvatinibe, ou um sal farmaceuticamente aceitável do mesmo. São também providos kits contendo tais agentes e usos de combinações terapêuticas de tais agentes para o tratamento de câncer.
BR112022026086A 2020-06-22 2021-06-21 Métodos para tratar câncer ou doença de von-hippel lindau e para tratar carcinoma de célula renal, kit, e, uso de uma combinação terapêutica BR112022026086A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063042225P 2020-06-22 2020-06-22
US202163146926P 2021-02-08 2021-02-08
PCT/US2021/038171 WO2021262562A2 (en) 2020-06-17 2021-06-21 Methods for treating cancer or von-hippel lindau disease using a combination of a pd-1 antagonist, a hif-2 alpha inhibitor, and lenvatinib or a pharmaceutically acceptable salt thereof

Publications (1)

Publication Number Publication Date
BR112022026086A2 true BR112022026086A2 (pt) 2023-03-07

Family

ID=85173740

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022026086A BR112022026086A2 (pt) 2020-06-22 2021-06-21 Métodos para tratar câncer ou doença de von-hippel lindau e para tratar carcinoma de célula renal, kit, e, uso de uma combinação terapêutica

Country Status (6)

Country Link
US (1) US20230250182A1 (pt)
JP (1) JP2023531930A (pt)
KR (1) KR20230026492A (pt)
BR (1) BR112022026086A2 (pt)
CA (1) CA3183862A1 (pt)
MX (1) MX2022016410A (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116063211B (zh) * 2023-02-14 2023-11-10 斯坦德药典标准物质研发(湖北)有限公司 一种Belzutifan的制备方法

Also Published As

Publication number Publication date
CA3183862A1 (en) 2021-12-30
MX2022016410A (es) 2023-04-05
US20230250182A1 (en) 2023-08-10
JP2023531930A (ja) 2023-07-26
KR20230026492A (ko) 2023-02-24

Similar Documents

Publication Publication Date Title
Buentzel et al. Intravenous amifostine during chemoradiotherapy for head-and-neck cancer: a randomized placebo-controlled phase III study
BRPI0409919A (pt) combinações para o tratamento de doenças envolvendo proliferação, migração ou apoptose celular de células de células de mieloma, ou angiogênese
BR112022009571A2 (pt) Uso de inibidor de fak na preparação de um fármaco para tratar tumores que têm mutação nras
BRPI0413974A (pt) combinação, método de tratamento de cáncer em um animal de sangue quente, composição farmacêutica, e, uso de uma combinação
AR095197A1 (es) Combinación de un inhibidor de egfr t790m y un inhibidor de egfr para el tratamiento del cáncer pulmonar de células no pequeñas
EA201391286A1 (ru) Лечение солидных опухолей
EA200600921A1 (ru) Способы и композиции с применением талидомида для лечения и менеджмента рака и других заболеваний
MX2023004156A (es) Terapia combinada para el tratamiento del cancer.
NO20024646L (no) Kombinasjonsterapier med vaskul¶r-skadende aktivitet
BR112021014854A2 (pt) Tratamento de lesões de pele e prurido em pacientes com prurigo nodularisis
BR112022010806A2 (pt) Métodos para tratar câncer de mama, para inibir o crescimento tumoral e para prevenir ou retardar o desenvolvimento de resistência de um câncer de mama
UA86586C2 (ru) Комбинация для лечения заболеваний, связанных с клеточной пролиферацией, миграцией или апоптозом клеток миеломы или с ангиогенезом
BR112021023110A2 (pt) Métodos de tratamento de síndrome de sjögren com o uso de um inibidor de tirosina quinase de bruton
UY31417A1 (es) Una composicion farmacéutica y un proceso para dicha composicion farmacéutica
WO2021262562A3 (en) Methods for treating cancer or von-hippel lindau disease using a combination of a pd-1 antagonist, a hif-2 alpha inhibitor, and lenvatinib or a pharmaceutically acceptable salt thereof
BR112021022602A2 (pt) Métodos para tratamento de urticária espontânea crônica com o uso de um inibidor de tirosina quinase de bruton
BR112022026086A2 (pt) Métodos para tratar câncer ou doença de von-hippel lindau e para tratar carcinoma de célula renal, kit, e, uso de uma combinação terapêutica
BR112022026094A2 (pt) Usos de um inibidor de hif-2a e lenvatinibe, ou um sal farmaceuticamente aceitável do mesmo, e de uma combinação terapêutica, e, kit
BR112022013143A2 (pt) Tratamento de combinação contra câncer usando um antagonista de pd-1, um antagonista de ilt4 e lenvatinibe ou sais dos mesmos
BR112022003220A2 (pt) Uma composição farmacêutica para tratar câncer usada para um paciente tendo marcador genético específico
BR112022012081A2 (pt) Método para tratar câncer, kit, e, uso de uma combinação terapêutica
Gecgel et al. Inhibition of telomerase potentiates enzalutamide efficiency of androgen-sensitive human prostate cancer cells
US10076520B2 (en) Use of tyrosine kinase inhibitor in cancer treatment
BR112022022304A2 (pt) Métodos para tratar câncer usando uma combinação de um antagonista pd-1, uma quimiorradioterapia e um inibidor de parp
BR0111900A (pt) Uso de um antagonista do receptor do tipo 1 da angiotensina ii, formulação farmacêutica, e, métodos para o tratamento de uma condição de cefaléia vascular e para o tratamento de enxaqueca